Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0345904 (liver cancer)
 15,188 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

Nineteen patients with metastatic liver tumor (9 of gastric cancer, 5 of colon cancer, 2 of pancreatic cancer, one each of mammary cancer, cholecystic cancer, carcinoid of biliary tract) and one patient with primary liver cancer were treated by endogenously induced LAK therapy consisting of transhepatic arterial infusion with ADM or MMC for induction therapy and OK-432 and rIL-2 (TGP-3) for immunotherapy. The following results were obtained. 1) Clinical response for liver tumor showed no CR but 8 cases of PR, for an overall response rate of 42.1%. 2) Reduced tumor marker value was noted in 76.5% cases, and 50% survival term became 349 days after the therapy. 3) Many CD4 and CD8 positive mononuclear cells had infiltrated around liver tumor after therapy by immuno-histochemical staining of surface marker. 4) NK activity of peripheral blood lymphocytes was markedly reduced soon after the therapy and continued for about 4-7 days, while in cases of combined subcutaneous administration with OK-432, NK activity showed only a slight decrease.
 ...
PMID:[Significance of antitumor effects and immunological response on endogenously induced LAK therapy for primary or metastatic liver tumor]. 153 Feb 92

A retrospective analysis of 35 stage IV HCC (26 IV-A case and 9 IV-B cases) which underwent reduction surgery from 1983 suggested a possibility to extend their survival period by decrease in their tumor-mass and subsequent immunochemotherapy for improvement of their depressed immunity. Their operability depended on the clinical stage of accompanying liver cirrhosis and extent of distant organ metastasis. It is of first importance for reduction surgery to select intrahepatic multiple tumors, slow-growing and not rapidly to induce distant organ metastases, among them. Intrahepatic tumors arising from multicentric origins were found in 42% in IV-A cases but 0% in IV-B. DNA ploidy analysis of the multicentric tumors in 8 cases did not show any clear indication of resectable tumors according to DNA index. The present immunochemotherapy is composed of a continuous infusion of IL2 and intermittent one-shot injections of 10mg ADR to the remnant liver by using subcutaneously implanted pump. In patients who could enhance peripheral NK and LAK activities by the immunotherapy, decreases in intra- and extra- hepatic tumors were observed. The 2 year-survival rate was 49% in IV-A, but only one case who is receiving the immunotherapy is surviving over 2 years in IV-B.
 ...
PMID:[Significance of reduction surgery for stage IV hepatocellular carcinoma (HCC) and postoperative immunochemotherapy for extension of survival period]. 165 92

Co-cultured subcloned LAK cell and human liver cancer cell (H7402) were fixed in situ for scanning electron microscopic and transmission electron microscopic examinations. The SEM and TEM findings gave a new evidence in answering how LAK cells kill the cancer cells. First, the activated killer cells recognized and made close contact with the target cell. Then some kind of lethal hit produced by intact killer cells was delivered, injuring the target cell, boring holes and pole-like tunnels on the cell surface or even penetrating into the cytoplasm of the cancer cells. Eventually, cell death in the manner of apoptosis and necrosis occurred as the end result of the damage to the cancer cell. These findings strongly support the idea that the death of the target cells is mediated by LAK cells.
 ...
PMID:[Ultrastructural study of the lethal effect of lymphokine activated killer (LAK) cell on liver cancer cells]. 178 88

Ten patients with advanced liver cancer, primary in 5 and metastatic in the other 5, were treated with lymphokine-activated killer cells, autologous (aLAK) and/or homologous (hLAK) combined with human natural IL-2. Each course of treatment lasted 10 days. For aLAK/IL-2 treatment, white cells were collected from the patients to be treated by a cell separator on Day 4 and after 3-day culture of the mononuclear cells in vitro in the presence of IL-2 (500 units/ml), the aLAK cells (1-2 x 10(9)) were transferred back to the patient on Day 7 via the hepatic artery by selective catheterization. IL-2 (20-30 x 10(4) units) was given i.v. daily on Days 1, 2, 8, 9 and 10. For hLAK/IL-2 treatment LAK cells from healthy donors (0.5-1 x 10(9)) were administered i.v. on Days 1, 4, and 7 and IL-2 (20-30 x 10(4) units) i.v. daily on Days 2, 3, 5, 6, 8, 9, 10. Patients with primary liver cancer were all treated with aLAL/IL-2, followed by hLAK/IL-2 in 3. Patients with metastatic cancer in the liver were either treated with hLAK/IL-2 alone or in combination with aLAK/IL-2. The results of the treatment as monitored by B ultrasonography, CT scan and digital selective angiography are as follows: CR in 2 (with metastatic liver cancer), PR in 4 (3 with primary and 1 with metastatic liver cancer), MR in 2 and no response in 2. On follow-up, 7 patients survived greater than 6 months and 1 (a complete responder) for greater than 12 months. Side effects were mild with transient fever up to 38.5 degrees C and general malaise.
 ...
PMID:[Treatment of advanced liver cancer by autologous and/or homologous LAK cells combined with human natural LL-2]. 187 94

Adherent lymphokine-activated killer cells (A-LAK cells) obtained from human peripheral blood mononuclear cells represent a population of potent antitumor effectors enriched in interleukin-2(IL-2)-activated natural killer cells. This study shows that A-LAK cells can be successfully generated from the blood of patients with liver cancer not treated with adjuvant chemotherapy or irradiation. Mononuclear cells were isolated from the blood of 33 patients with liver tumors (6 benign, 10 primary malignant, 17 metastatic) at the time of liver resection. A-LAK cells were separated by adherence to plastic following activation of peripheral blood mononuclear cells in 1000 U/ml recombinant IL-2. A-LAK cells (enriched up to 92% in CD3-CD56+ cells) showed better subsequent expansion and two to six times higher antitumor cytotoxicity per cell than unseparated LAK cells cultured under the same conditions. The ability to generate A-LAK cells with superior in vitro cytotoxicity from the blood of most patients with liver cancer indicates that adoptive cellular immunotherapy may be a feasible and new way of treatment for primary and secondary hepatic neoplasms in man.
 ...
PMID:Unimpaired ability to generate adherent lymphokine-activated killer (A-LAK) cells in patients with primary or metastatic liver tumors. 262 25

For the purpose of establishing a new in vitro model of adoptive immunotherapy, we synthesized two kinds of bispecific antibodies (BsAbs), i.e., (OK x L) BsAbs constructed with both OKT-3 (anti-CD3) and L-7-6 (anti-HCC), and (3G x L) BsAbs constructed with 3-G-8 (anti-CD16) and L-7-6 antibodies. These two BsAbs, having pairs of binding arms on their single molecule, showed similar binding to target cells as the parental monoclonal antibodies (OKT-3, 3-G-8 and L-7-6), when examined with FACS. Newly devised in vitro cytotoxicity tests revealed that LAK or PWM-stimulated LAK (PWM-LAK) cells did not show any significant cytotoxic activity to HCC cells, while both effector cells equally showed greatly enhanced cytotoxicity to HCC even at a low effector/target (0.3) in the presence of BsAbs (OK x L) for the efficient retargeting of the effector cells. Inasmuch as PWM-LAK cells proliferate in vitro 3-5 times faster than LAK cells, adoptive immunotherapy using PWM-LAK cells in combination with (OK x L) BsAbs should be very promising.
 ...
PMID:A new in vitro model of specific targeting therapy of cancer: retargeting of PWM-LAK cells with bispecific antibodies greatly enhances cytotoxicity to hepatocellular carcinoma. 872 93

AIM:To observe the therapeutic effects of Sishengtang decoction in alleviating the toxic and side effects of transarterial embolization (TAE).METHODS: Fifty-four patients with liver cancer were divided randomly into Sishengtang decoction group (34 cases) and control group (20 cases).The changes of clinical symptoms and peripheral hemogram and some cellular immune functions were observed before and two weeks after TAE.RESULTS:Sishengtang decoction was superior to the control group in improving the digestive tract reaction.The leucocytes of peripheral blood and cellular immune functions (activities of NK cells and LAK cells) of control group decreased obviously after TAE, while that of Sishengtang decoction group decreased slightly, without obvious difference as compared with that of preoperation.CONCLUSION:Sishengtang decoction might improve the clinical symptoms and increase the leucocytes of peripheral blood and the cellular immune functions of TAE patients.
 ...
PMID:Sishengtang decoction in alleviation of toxic and side effects of transarterial embolization. 1181 67